Compare APAM & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | VRDN |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2013 | N/A |
| Metric | APAM | VRDN |
|---|---|---|
| Price | $44.37 | $33.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $46.00 | $41.17 |
| AVG Volume (30 Days) | 397.5K | ★ 1.4M |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 8.19% | N/A |
| EPS Growth | ★ 2.95 | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $1,158,234,000.00 | $70,789,000.00 |
| Revenue This Year | $8.56 | $26,257.62 |
| Revenue Next Year | $7.04 | $4.54 |
| P/E Ratio | $11.96 | ★ N/A |
| Revenue Growth | 8.88 | ★ 23340.07 |
| 52 Week Low | $32.75 | $9.90 |
| 52 Week High | $48.50 | $34.29 |
| Indicator | APAM | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 61.39 | 60.22 |
| Support Level | $42.27 | $29.63 |
| Resistance Level | $44.77 | $34.29 |
| Average True Range (ATR) | 1.02 | 1.29 |
| MACD | 0.25 | 0.14 |
| Stochastic Oscillator | 89.46 | 81.71 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).